Health Care • Biotechnology: Pharmaceutical Preparations
$0.77 ▼ -0.04
(-5.52%)
MKT CAP: $52.3M • VOL: 214.3K
52W L $1 52W H $4
IBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $400.0K | $225.0K | $0 |
| YoY Revenue Growth % | +77.8% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$18.6M | -$16.6M | -$29.3M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$18.4M | -$24.9M | -$65.0M |
| EBITDA (Normalized) | -$18.6M | -$16.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$15.3M | -$18.6M | -$30.4M |
| Capital Expenditures (CapEx) | $16.0K | $210.0K | — |
| Free Cash Flow (FCF) | -$15.3M | -$18.8M | -$30.4M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $28.7M | $7.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $56.6M | $13.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IBIO.